8-K

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 24, 2022

OncocyteCorporation

(Exact name of registrant as specified in its charter)

15Cushing

Irvine,California 92618

(Address of principal executive offices)

(949)409-7600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Forward-LookingStatements

Anystatements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,”“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”)should be considered to be forward-looking statements. Factors that could cause actual results to differ materially from the resultsanticipated in these forward-looking statements are contained in Oncocyte Corporation’s Annual Report on Form 10-K filed with theSecurities and Exchange Commission (“SEC”) under the heading “Risk Factors” and in other filings that Oncocytemay make with the SEC. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they aremade, and the facts and assumptions underlying these statements may change. Except as required by law, Oncocyte disclaims any intentor obligation to update these forward-looking statements.

Referencesto “Oncocyte,” the “Company,” we,” “us,” and “our” are references to Oncocyte Corporation.

Item5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangementsof Certain Officers.

Effective June 24, 2022, Li Yu resigned as Vice President, Controller, and Principal Accounting Officer of the Company. Ms. Yu resigned to pursue other opportunities, and there were no disagreements between the Company and Ms. Yu on any matter regarding its operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.